

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 23, 2021

General Electric Company

(Exact name of registrant as specified in its charter)

New York (State or other jurisdiction of incorporation)	001-00035 (Commission File Number)	14-0689340 (IRS Employer Identification No.)
5 Necco Street Boston, MA (Address of principal executive offices)		02210 (Zip Code)

(Registrant's telephone number, including area code) **(617) 443-3000**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.01 per share	GE	New York Stock Exchange
0.375% Notes due 2022	GE 22A	New York Stock Exchange
1.250% Notes due 2023	GE 23E	New York Stock Exchange
0.875% Notes due 2025	GE 25	New York Stock Exchange
1.875% Notes due 2027	GE 27E	New York Stock Exchange
1.500% Notes due 2029	GE 29	New York Stock Exchange
7 1/2% Guaranteed Subordinated Notes due 2035	GE /35	New York Stock Exchange
2.125% Notes due 2037	GE 37	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On September 23, 2021, General Electric Company issued a press release announcing the entry into an agreement to acquire BK Medical, a leader in advanced surgical visualization, from Altaris Capital Partners for a cash purchase price of \$1.45 billion. The parties expect the transaction to close in 2022, subject to review by the relevant regulatory authorities.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 is being furnished as part of this report.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release, dated September 23, 2021 issued by General Electric Company
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

This document contains "forward-looking statements"-that is, statements related to future, not past, events. These forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "estimate," "forecast," "target," "preliminary," or "range." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, and are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) that one or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction, may require conditions, limitations or restrictions in connection with such approvals; (2) the risk that the proposed transaction may not be completed in the expected time frame, or at all; (3) uncertainty of the expected financial performance of GE Healthcare or BK Medical following completion of the proposed transaction, or failure to realize the anticipated benefits of the proposed transaction; and (4) other risk factors as detailed from time to time in GE's reports filed with the SEC, including GE's annual report on Forms 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

General Electric Company _____
(Registrant)

Date: September 23, 2021

/s/ Michael J. Holston _____
Michael J. Holston
Senior Vice President, General Counsel and
Secretary

GE Healthcare to Acquire BK Medical, Expanding Ultrasound Portfolio into Surgical Visualization

- *Complementary acquisition supports GE Healthcare's \$3 billion Ultrasound business' expansion from diagnostics into surgical and therapeutic interventions*
- *Creates compelling customer offering and accelerates GE Healthcare's growth in precision health*
- *Adds capability in fast-growing advanced surgical visualization segment; attractive-margin business serving accretive, high-growth segments*

BOSTON - September 23, 2021 - GE (NYSE:GE) has entered into an agreement to acquire BK Medical, a leader in advanced surgical visualization, from Altaris Capital Partners for a cash purchase price of \$1.45 billion.

BK Medical is an innovator in global intraoperative imaging and surgical navigation, used to guide clinicians during minimally invasive and robotic surgeries and to visualize deep tissue during procedures in neuro and abdominal surgery, and in ultrasound urology. BK Medical is headquartered in Boston and Copenhagen with more than 650 employees and is delivering double-digit revenue growth.

GE Healthcare President and CEO Kieran Murphy said, "Ultrasound today forms an integral part of many care pathways, and BK Medical is a strategic and highly complementary addition to our growing and profitable Ultrasound business. This transaction helps GE Healthcare continue to expand beyond diagnostics into surgical and therapeutic interventions, simplifying decision-making for clinicians and equipping them with greater insights to deliver faster, more personalized care for their patients-representing another step toward delivering precision health."

BK Medical President and CEO Brooks West said, "We are immensely proud of the organization and of the life-changing technology that we have built at BK Medical, and look forward to our future as part of the GE Healthcare family. Combining our expertise in intraoperative imaging and surgical navigation with GE Healthcare's many strengths and global presence will accelerate our mission to change the standard of care in surgical interventions. Our mission to help surgeons make critical decisions using active imaging aligns well with GE Healthcare's mission to help physicians make more informed decisions and improve patient outcomes, and we are eager to begin this new chapter."

GE Healthcare Ultrasound President and CEO Roland Rott said, "Adding the fast-growing and relatively new field of real-time surgical visualization to GE's pre- and post-operative Ultrasound capabilities will create an end-to-end offering through the full continuum of care-from diagnosis through therapy and beyond. GE Healthcare and BK Medical share a passion for clinical innovation, and I'm excited to welcome BK Medical to our team."

This transaction is expected to create value by further strengthening BK Medical, including through significant synergies with the benefit of GE's technology and commercial scale. This transaction enables BK Medical's Active Imaging platform to reach new customers and new markets around the world, and the combination of GE Healthcare's diagnostic imaging technology with BK's ability to enable decision-making and surgical visualization in intervention will allow better decision-making throughout the care continuum. GE Healthcare expects BK Medical to deliver rapid revenue growth as well as margin expansion and free cash flow growth. GE Healthcare also expects high-single-digit return on invested capital by year five.

The parties expect the transaction to close in 2022, subject to review by the relevant regulatory authorities.

Evercore acted as exclusive financial advisor to GE on the transaction. Gibson, Dunn and Crutcher acted as legal advisor to GE. J.P. Morgan Securities LLC served as lead financial advisor, Morgan Stanley & Co. LLC served as financial advisor, and Latham Watkins LLP and Schiff Hardin LLP acted as legal advisor to BK Medical.

Forward-looking statements

This document contains "forward-looking statements"-that is, statements related to future, not past, events. These forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "estimate," "forecast," "target," "preliminary," or "range." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, and are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) that one or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction, may require conditions, limitations or restrictions in connection with such approvals; (2) the risk that the proposed transaction may not be completed in the expected time frame, or at all; (3) uncertainty of the expected financial performance of GE Healthcare or BK Medical following completion of the proposed transaction, or failure to realize the anticipated benefits of the proposed transaction; and (4) other risk factors as detailed from time to time in GE's reports filed with the SEC, including GE's annual report on Forms 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive.

About GE

GE (NYSE:GE) rises to the challenge of building a world that works. For more than 125 years, GE has invented the future of industry, and today the company's dedicated team, leading technology, and global reach and capabilities help the world work more efficiently, reliably, and safely. GE's people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill GE's mission and deliver for its customers. www.ge.com

About GE Healthcare:

GE Healthcare is the \$17 billion* healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on [Facebook](#), [LinkedIn](#), [Twitter](#), and [Insights](#) for the latest news, or visit our website www.gehealthcare.com for more information.

**Excluding BioPharma.*

About BK Medical

BK Medical is a global intraoperative imaging and surgical navigation company with headquarters in Boston and Copenhagen and more than 650 employees worldwide. Through the advanced ultrasound technology and sophisticated software algorithms of its active imaging platform, BK Medical enables surgeons to make real-time, data-based decisions during surgical procedures, resulting in better clinical outcomes and reduced costs for patients, physicians, and the healthcare system. With 40 years of expertise in advanced ultrasound technology, the company has a global installed base of more than 14,000 ultrasound platforms. BK Medical technology is highly proprietary and protected with more than 136 patent families. For more information, please visit www.bkmedical.com.

About Altaris

Altaris is an investment firm focused exclusively on the healthcare industry. Altaris seeks to invest in companies that deliver value to the healthcare system and improve patient outcomes by providing innovative products and services. Since inception in 2003, Altaris has invested in more than 40 companies across its five main investment funds. Altaris has \$5.9 billion of equity capital under active management and is headquartered in New York, NY. For more information, please visit www.altariscap.com.

GE Healthcare Media Contacts

Jennifer Fox
+1 414 530 3027
Jennifer.R.Fox@ge.com

Hannah Huntly
GE Healthcare
Hannah.huntly@ge.com
+44 7887 824201

BK Medical Media Contact

Jehana Ray
857.995.7449
jray@bkmedical.com

GE Investor Contact

Steve Winoker
617.443.3400
swinoker@ge.com

GE Media Contact

Mary Kate Mullaney
202.304.6514
marykate.nevin@ge.com